S-1: Picard Medical Files for IPO to Advance Artificial Heart Technology

Picard Medical, a company focused on artificial heart technology, has filed an S-1 registration statement for an initial public offering.

Summary

• Picard Medical, Inc., a holding company owning SynCardia Systems, LLC, has filed for an initial public offering.
• SynCardia manufactures and sells the SynCardia Total Artificial Heart (TAH), the only FDA and Health Canada approved implantable TAH.
• Over 2,100 SynCardia TAHs have been implanted in 27 countries.
• The company's future vision is to develop a fully implantable SynCardia TAH as an alternative to heart transplantation.
• Near-term product developments include innovating driver technology and expanding the indication for use to Bridge to Candidacy (BTC) and long-term use.
• The next-generation Emperor Total Artificial Heart is expected to be fully implantable and undergoing non-clinical bench testing, with potential FDA approval in 2028.
• The company is working on product upgrades, including the Freedom+ Driver, expected to be approved in the second half of 2025.
• A next-generation pneumatic driver system, Unicorn, is under development, with regulatory testing expected in the second half of 2026.
• The company plans to submit a 180-day PMA supplement to remove 'imminent death' and add BTC to the SynCardia TAH IFU, with an answer expected from the FDA in the third quarter of 2025.
• The company is also addressing a field correction related to cannula tears, with a design change submission expected to the FDA in the third quarter of 2025.
• The company estimates approximately 15 million people with heart failure per year in the EU, up to approximately 4.6 million in India, approximately 12 million in China, and approximately 3.75 million in the Middle East.
• The Investment Agreement with SynCardia Medical (Beijing), Inc. is contingent on Picard Medical becoming publicly traded on a stock exchange.
• The company has a history of significant losses and expects to continue incurring losses for the foreseeable future.
• The company acknowledges substantial doubt about its ability to continue as a going concern without raising additional capital.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has a unique product and is pursuing growth opportunities, it also faces significant financial challenges and regulatory hurdles.

Positives

• The SynCardia TAH is the only FDA and Health Canada approved implantable total artificial heart.
• The company is actively working on product upgrades and new product development to improve clinical outcomes and patient quality of life.
• The company is expanding its international presence through a joint venture in China.
• The company has a strong track record with over 2,100 SynCardia TAH implants to date.
• The company has a successful training and education program for surgeons and supporting teams.

Negatives

• The company has a history of significant losses and expects to continue incurring losses for the foreseeable future.
• The company acknowledges substantial doubt about its ability to continue as a going concern without raising additional capital.
• The company relies on specialized suppliers and service providers for components of the SynCardia TAH and does not have second-source suppliers for the majority of components.
• The company has significant customer concentrations and has no long-term exclusive agreements with its customers.
• The company voluntarily withdrew its CE certificate under CE MDD in 2022 and failure to reinstate our CE certificate under CE MDR could have a material adverse effect on our business.

Risks

• The company has a history of significant losses and may not achieve or sustain profitability.
• The company's ability to manufacture the SynCardia TAH on a timely basis is dependent on specialized knowledge and operator skills.
• The company relies on specialized suppliers and service providers for components of the SynCardia TAH and does not have second-source suppliers for the majority of components.
• The company has significant customer concentrations and has no long-term exclusive agreements with its customers.
• The company's future success depends on its ability to develop, receive regulatory approval for, and introduce new products or product enhancements.
• The company may need to undertake additional clinical trials in order to secure from the FDA an expansion of the indication for the SynCardia TAH from Bridge-to-Transplant (BTT) to Long-Term (LT).
• Failure to reinstate our CE certificate under CE MDR could have a material adverse effect on our business.
• Many aspects of the SynCardia TAH are no longer protected by patents, and the company may be unable to protect its products from competition through other means.
• The company's share price may be volatile, and purchasers of its securities could incur substantial losses.
• The company's classification as an emerging growth company and a smaller reporting company could make its securities less attractive to investors.
• The company does not intend to pay cash dividends for the foreseeable future.
• Future sales of common stock may cause the market price of common stock to decline.
• The company will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies.
• The company could be subject to securities class action or derivative litigation.
• If the company is unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of its financial reports and the market price of common stock may decrease.
• The company's common stock has no prior market, and its stock price may decline after the offering.
• The company's stockholders may be subject to significant dilution upon the occurrence of certain events, including conversion of its Series A-1 Preferred Shares and certain related party loans into shares of its common stock, which could result in volatility in its stock price.
• An active trading market may not develop or be sustained.
• The company intends to rely on certain controlled company corporate governance exemptions following this offering while it search for candidates to serve as independent directors, and accordingly, its stockholders will not have the same protections afforded to stockholders of companies that are subject to such requirements.
• Exclusive forum provisions in the company's certificate of incorporation could limit its stockholders ability to bring, and increase the costs of, a claim in a judicial forum that it finds favorable for disputes with the company or its directors, officers, or employees.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it continues to sell and market, research and develop and seek regulatory approvals for existing and future products. The company also expects to incur additional expenses with transitioning to, and operating as, a public company.

Management Comments

• Our future vision is to develop the worlds first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world.

Industry Context

Cardiovascular disease is the leading cause of death in the United States and globally. Heart transplantation is the treatment of choice for carefully selected patients with advanced or end-stage heart failure, but the demand for donor hearts exceeds the available supply.

Comparison to Industry Standards

• The SynCardia TAH is the only total artificial heart that is approved for commercial use in the United States and Canada.
• Carmat's Aeson device is approved for commercial use in the EU only (CE mark).
• The BiVACOR system has not obtained approval for any market to date.
• Cardiologists are also using LVADs and other temporary MCS, including extracorporeal membrane oxygenation (ECMO), or axial flow percutaneous left ventricular assist devices to bridge patients with biventricular heart failure to transplantation.
• The average selling price of the Abbott HeartMate 3 (LVAD) is around $120,000, between $20,000 and 30,000 for the Abiomed Impella 2.5 and 5.0 devices (axial flow percutaneous left ventricular assist devices), and around $111,000 for the Getinge CardioHelp device and (ECMO).

Related Party Transactions

• The company has engaged in numerous related party transactions, including loans from affiliated entities and individuals.
• Richard Fang, former Chief Executive Officer and current director, has donated the $7.0 million aggregated convertible note, dated July 2, 2024, and the related accrued interest, to the unrelated not-for-profit organizations, Nexus Science Foundation Inc. (Nexus), and Another Dimension Foundation (Another Dimension).

Stakeholder Impact

• The company's success will impact patients with advanced heart failure, healthcare providers, and investors.
• The company's ability to continue as a going concern is dependent on its ability to raise additional funds and financing, including through the consummation of this offering.

Next Steps

• Complete acute animal studies using selected Emperor design prototypes during the first half of 2025.
• File a design change to address the cannula tears with the FDA via a 180 Day PMA Supplement in approximately the third quarter of 2025.
• Obtain FDA approval of the upgraded portable driver system called Freedom+ by the second half of 2025.
• Complete the regulatory testing of the Unicorn driver in the second half of 2026.
• Gain FDA approvals for next generation Freedom and C2 Drivers during the second halves of 2026 and 2027, respectively.
• Continue discussions with the FDA to expand the SynCardia TAH IFU.

Key Dates

Keywords

SynCardia TAH, total artificial heart, heart failure, medical device, FDA approval, BTT, BTC, Emperor, Freedom Driver, Unicorn, Hunniwell Picard, IPO